In vivo hæmmer cetuximab tumorcellers angiogene faktorer og fremkalder en reduktion i tumorens neo- vaskularisering og metastasering.
In vivo cetuximab inhibits expression of angiogenic factors by tumour cells and causes a reduction in tumour neo-vascularisation and metastasis.